Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas

The PI3K/Akt/mTOR (PAM) axis is constitutively activated in multiple lymphoma subtypes and is a promising therapeutic target. The mTOR inhibitor temsirolimus (TEM) and the immunomodulatory agent lenalidomide (LEN) have overlapping effects within the PAM axis with synergistic potential. This multicen...

Descripción completa

Detalles Bibliográficos
Autores principales: Major, Ajay, Kline, Justin, Karrison, Theodore G., Fishkin, Paul A. S., Kimball, Amy S., Petrich, Adam M., Nattam, Sreenivasa, Rao, Krishna, Sleckman, Bethany G., Cohen, Kenneth, van Besien, Koen, Rapoport, Aaron P., Smith, Sonali M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2021
Materias:
Article - Non-Hodgkin Lymphoma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244831/
https://www.ncbi.nlm.nih.gov/pubmed/34320785
http://dx.doi.org/10.3324/haematol.2021.278853

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244831/
https://www.ncbi.nlm.nih.gov/pubmed/34320785
http://dx.doi.org/10.3324/haematol.2021.278853

Ejemplares similares